Cooley-Led Biotech Firm Launches Plans For $350M IPO
Inflammatory-disease focused drug developer Acelyrin Inc. set a price range on an estimated $350 million initial public offering on Monday, eyeing potentially the largest biotechnology IPO since June 2021, represented by...To view the full article, register now.
Already a subscriber? Click here to view full article